Search
Spotlight
Diabetes
Women's Health
Diabetes
Women's Health
Clinical
View More
Cardiology
Cardiovascular Disease
Cushing's Disease
Diabetes
Endocrine Diseases
Endocrinology
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Cancer
Thyroid Disorders
Weight Management
Women's Health
Cardiology
Cardiovascular Disease
Cushing's Disease
Diabetes
Endocrine Diseases
Endocrinology
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Cancer
Thyroid Disorders
Weight Management
Women's Health
News
Media
Expert Interviews
Medical World News
Podcasts
Expert Interviews
Medical World News
Podcasts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Columns
Resources
CME/CE
Clinical Guidelines
Image IQ
Partners
Webinars
CME/CE
Clinical Guidelines
Image IQ
Partners
Webinars
Subscribe
Search
Spotlight
Diabetes
Women's Health
Clinical
See All >
Cardiology
Cardiovascular Disease
Cushing's Disease
Diabetes
Endocrine Diseases
Endocrinology
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Cancer
Thyroid Disorders
Weight Management
Women's Health
SGLT2 + GLP-1 =
May 19, 2015
Payal Kohli, MD
Payal Kohli, MD
Combination therapy with an SGLT2 inhibitor and GLP-1 receptor agonist:
A. Is safe and well tolerated
B. Achieves double the weight loss of a SGLT2 inhibitor alone
C. Is additive with respect to its effects on weight loss.
D. All of the above
E. None of the above
Vote